Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1996-02-28
1998-04-14
Russel, Jeffrey E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 16, 514 17, 514 18, A61K 3807, A61K 3808
Patent
active
057391092
ABSTRACT:
The present invention relates to a method of treating neuroinflammatory degenerative diseases which are cytokine mediated. The method involves administration of an effective amount of Peptide T or a related Peptide to diminish, halt or reverse the patient's loss of function due to neuroinflammation.
REFERENCES:
patent: 5063206 (1991-11-01), Bridge et al.
patent: 5189022 (1993-02-01), Bridge et al.
patent: 5192753 (1993-03-01), McGeer et al.
patent: 5194448 (1993-03-01), Coupland et al.
patent: 5248667 (1993-09-01), Bridge et al.
patent: 5276016 (1994-01-01), Pert et al.
patent: 5434170 (1995-07-01), Andrulis, Jr.
patent: 5446026 (1995-08-01), Ruff et al.
patent: 5534495 (1996-07-01), Pert et al.
patent: 5545656 (1996-08-01), Loose et al.
patent: 5550132 (1996-08-01), Benson et al.
patent: 5567682 (1996-10-01), Pert
patent: 5593991 (1997-01-01), Adams et al.
patent: 5686417 (1997-11-01), MacFadden et al.
Pert, et al. AIDS and Its Dementia as a Neuropeptide Disorder: Role of VIP Receptor Blockade by Human Immunodificiency Virus Envelope, Annals of Neurology Suppl. to vol. 23, 1988, pp. 571-573.
Bridge, et al. PHASE I of Peptide T in Aids Patients and Controls, International Conference on Aids, Jun. 12-16, 1988 Stockholm, Sweden.
Heseltine, et al. Phase I of Peptide T in Aids: Pharmacology and Immune Response, INt'l Conference on Aids, Jun. 12-16, 1988, Stockholm, Sweden.
Jaffe, et al., Isolation and Identification of a Peptide form Rat Brain 239-245, 1990.
Michael R. Ruff, et al., Pharmacokinetics of Peptide T in Patients with Acquired Immunodeficiency Syndrome (Aids), Prog. Neuro-Psychopharmacol & Biol. Psychiat. 1991, vol. 15, pp. 791-801.
Ruff, et al. Cytokine Changes in Adult HIV Patients Receiving Peptide T, Portland, 1994.
D.J. Socci, et al., Chronic Peptide T Administration Prevents Neocortical Atrophy Resulting from Nucleus Basalis Lesions in Aged Rats, Society for Neurocience Abstracts, vol. 18, 1992.
J.A. Marcusson, et al., Peptide-T in the Treatment of Psoriasis and Psoriatic Arthritis, A case report, Acta Derm Venereol (Stockh) 69, 1989, pp. 86-88.
Rodgers-Johnson, et al., Tropical Spastic Paraparesis and HTLV-I-Associated Myelopathy-Clinical and Laboratory Diagnosis, Human Retrovirology: HTLV edited by W.A. Blattner, Raven Press, Ltd., NY 1990, pp. 205-211.
Marcusson, et al., Peptide T and Psoriasis, Acta Derm Venereol (Stockh) 1989; Suppl. 146: 117-121.
Ruff, et al., CD4 receptor binding peptides that block HIV infectivity cause human monocyte chemotaxis, FEB 04365, vol. 211, No. 1, 17-22, Jan. 1987.
Raj, et al., Identification and Characterization of a Novel GGA/C-Binding Protein, GBP-i, That is Rapidly Inducible by Cytokines, Molecular and Cellular Biology, Dec. 1994, pp. 7770-7781.
Dalgleish, et al., The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus, Nature, vol. 312 20/27 Dec. 1994, pp. 763-7.
Brenneman, et al., Neuronal cell killing by the envelope protein of HIV and its prevention by vasoactive intestinal peptide, Nature, vol. 353, No. 6191, pp. 639-642, 13 Oct. 1988.
Pert, et al., Octapeptides deduced from the neuropeptide receptor-like pattern of antigen T4 in brain potently inhibit human immunodeficiency virus receptor binding and T-cell infectivity, Porc. Natl. Acad Sci. USA, vol. 83, pp. 9254-9258, Dec. 1986, Neurobiology.
Pert, et al., Neuropeptides and their Receptors: A Psychosomatic Network, The Journal of Immunology, vol. 135, No. 2, Aug. 1985, pp. 820s-826s.
Nagano et al. Expression of cytokines in brain lesions . . . Neurology. Apr. 1994, vol. 44, pp. 710-715.
Adams MerriBeth
Casciato Dennis A.
Davis Michael A.
Galpin Jeffrey E.
Globe Gary
Advanced Immunit Inc.
Russel Jeffrey E.
LandOfFree
Method of treating neuroinflammatory degenerative diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating neuroinflammatory degenerative diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating neuroinflammatory degenerative diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-634608